Rolling Mill Bearings,Four-Row Cylindrical Roller Bearing,Industry Rolling Mill Bearing,Lifting Transport Machinery Bearing Jinan Bosch Bearing Co.,Ltd , https://www.bosch-bearing.com
According to relevant persons from the China Medicare Association, this year's domestic chemical raw material pharmaceutical industry is facing tremendous pressure from inside and outside. In China, the appreciation of the renminbi and the reduction of export tax rebate rate have affected the normal production and fulfillment capabilities of enterprises, which has weakened the competitiveness of China's chemical raw materials in the international market to some extent. At the same time, the state's inspection procedures for the export of pharmaceuticals have become more and more stringent, which has lengthened the delivery time of chemical products and increased the cost of storage and transportation. In the international arena, the Panama diethylene glycol incident in April this year caused a certain degree of adverse impact on the international image of China's chemical raw material pharmaceutical products. The EU REACH regulation was formally in force and the EU has completely banned food animals from using antibiotics to promote growth since last year. The provisions of additives also increase the difficulty of exporting chemical raw materials in China. Under such internal and external pressures, the export of chemical raw materials in China continues to grow at a high rate. The main reason is that there has been a major shift in China's chemical raw material medicine market this year. After the price war in recent years, some bulk raw medicines have gradually come out of the doldrums, showing a trend of simultaneous increase in production, sales volume, export volume, and prices. Among them, the production of penicillins, water-soluble vitamins, erythromycin thiocyanate, tylosin and other varieties increased, and the prices soared. The influence and importance of China's chemical raw material drugs in the world's pharmaceutical industry have been continuously improved, and the world's pharmaceutical industry's processing and procurement focus has shifted to China, providing good opportunities for the acceleration of China's chemical raw material drug exports.
Faced with the good situation of this year's exports, Zhou Xiaoming, president of the China Medicare Association, reminded that the proportion of products with independent intellectual property rights in China's chemical raw material pharmaceutical industry is still very small, and the investment in research and development of new products is very low, with high energy consumption and low added value. The proportion of products is too large. Therefore, to ensure the sustainable growth of chemical raw material exports, we must not work hard in these areas.
According to the reporter’s understanding, on January 1 next year, China will formally implement the “Pollutant Pollutant Discharge Standards for the Pharmaceutical Industryâ€, which will have a great impact on chemical raw material drug companies. However, if the production enterprises do not solve the issue of pollutant discharge standards, they will not be able to adapt to more and more stringent export technical barriers in the future.
On December 7, the reporter learned from the China Chamber of Commerce for the Import and Export of Medicines and Health Products that despite a series of pressures, China's exports of chemical raw materials have continued to increase substantially this year. The latest statistics show that in the first 8 months, China's total export of chemical raw materials was 5.8 billion U.S. dollars, an increase of 35% year-on-year, and it is expected to grow by 30% for the whole year, accounting for 84% of the national pharmaceutical export share.
December 23, 2022